Evidence on the Benefits and Harms of Screening and Treating Pregnant Women Who Are Asymptomatic for Bacterial Vaginosis: An Update Review for the U.S. Preventive Services Task Force

Established in 1927 by the American College of Physicians

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

Evidence on the Benefits and Harms of Screening and Treating Pregnant Women Who Are Asymptomatic for Bacterial Vaginosis: An Update Review for the U.S. Preventive Services Task Force

View larger version (42K):
[in this window]
[in a new window]

Figure 1. Analytic framework and key questions.

KQ = key question.

View this table:
[in this window]
[in a new window]

Appendix Table 1. Overall Searches ${webonly}$

View this table:
[in this window]
[in a new window]

Appendix Table 2. Specific Searches per Key Question* ${webonly}$

View this table:
[in this window]
[in a new window]

Appendix Table 3. U.S. Preventive Services Task Force Quality Rating Criteria ${webonly}$

View this table:
[in this window]
[in a new window]

Appendix Table 4. Jadad Scale Criteria ${webonly}$

View this table:
[in this window]
[in a new window]

Appendix Table 5. Jadad Score Calculation ${webonly}$

View larger version (44K):
[in this window]
[in a new window]

Figure 2. Search and selection of literature for all key questions.

BV = bacterial vaginosis; RCT = randomized, controlled trial. *Cochrane databases include the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Database of Abstracts of Reviews of Effects. ${dagger}$ Other sources include reference lists and expert suggestions. ${ddagger}$ We included 7 additional studies for key question 2 and 2 for key question 3 from the 2001 report in the summary of this evidence.

View larger version (19K):
[in this window]
[in a new window]

Figure 3. Study characteristics and absolute risk reduction of delivery before 37 weeks.

Span = treatment timing spans less than 20 weeks and greater than 20 weeks. *Baseline risk is the percentage of deliveries before 37 weeks in the placebo group. Absolute risk reduction is the difference in probability of delivery before 37 weeks (control minus treatment). ${dagger}$ McDonald et al. (58) and Carey et al. (57) performed a high-risk group subanalysis; high-risk group is included in total study population of the average-risk target group. Odendaal et al. (50) included 2 target populations; high-risk and low-risk groups are 2 separate groups.

View larger version (10K):
[in this window]
[in a new window]

Figure 4. Absolute risk reduction of delivery before 34 weeks and before 32 weeks.

PTD = preterm delivery. *McDonald et al. (58) and Carey et al. (57) performed a high-risk group subanalysis; high-risk group is included in total study population of the average-risk target group. Odendaal et al. (50) included 2 target populations; high-risk and low-risk groups are 2 separate groups.

View larger version (19K):
[in this window]
[in a new window]

Figure 5. Absolute risk reduction of low birthweight and preterm, premature rupture of membranes (PPROM).

*McDonald et al. (58) and Carey et al. (57) performed a high-risk group subanalysis; high-risk group is included in total study population of the average-risk target group.

View this table:
[in this window]
[in a new window]

Table 1. Characteristics of Studies of Women at High Risk for Delivery before 37 Weeks*

View this table:
[in this window]
[in a new window]

Table 2. Outcomes Table: Benefits and Harms of Screening 1000 Pregnant Women at High Risk for Bacterial Vaginosis*

View larger version (45K):
[in this window]
[in a new window]

Appendix Figure. Illustration of calculation in Table 2, using the outcome of delivery before 34 weeks in the more selective high-risk group. ${webonly}$

BV = bacterial vaginosis; PTD = preterm delivery. *To calculate the confidence limits for the increase or decrease in adverse outcome, plug in the confidence limits of effect size here. ${dagger}$ A negative sign (–) indicates a net increase in adverse outcomes (harm), and a positive sign (+) indicates a net decrease in adverse outcomes (benefit).